ALFA Finder| Revenue growth | FY26 revenue ₹270.17 Cr, down 7.7% YoY. |
|---|---|
| Margins | Gross margin improved 80 bps to 44.2% on better mix. |
| Order book | 964 total registered products; 200+ in pipeline. |
| Demand visibility | Strong growth in LATAM; 49 new product registrations secured. |
| Management confidence | High on backward integration and LATAM market diversification. |
Growth
FY26 Consolidated Revenue down 7.7% YoY; PAT fell 94.3% to ₹1.42 Cr; LATAM revenue grew 11% YoY.
Outlook
Received manufacturing license for Hyderabad facility; targeting WHO-GMP certification and deeper penetration in Latin America and Africa.
Risks
Extended working capital cycles in institutional business, particularly in Angola; exit from ancillary Building Hardware business.
Earnings Call filed with NSE, NSE: BALAXI. Summary written with AI assistance from the document.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹23.35
- Market cap
- ₹128.9 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 53.2×Sector 43.8×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Q2 FY27 Results: Net Profit ₹1.2 Cr, Up 500.0% YoY
Balaxi Pharmaceuticals Ltd reported revenue from operations of ₹81.4 Cr (+44.8% YoY) and net profit of ₹1.2 Cr (+500.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1.2 Cr · +500.0% YoY
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals filed its RTA report for October 2026 on re-lodgement of physical share transfers. All request counts for the month are NIL.
Balaxi Pharmaceuticals Board Meeting Date
Balaxi Pharmaceuticals will meet on 12 November 2026 to approve unaudited half-year results. The trading window stays closed until 14 November 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals Limited reported nil activity regarding the re-lodgement of physical share transfer requests for the period ended September 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.